Obermatt
See Similar Stocks →

Flags

Financial distress

Curaleaf Holdings

TOR:CURA · CA23126M1023
PharmaceuticalsLarge

360

14
EV / EBIT1
Price / Owner Earnings3
Owner Earnings Yield30
Dividend Yield1
Price/Sales67
EV / Gross Profit43
Price/Book27
Return on Capital29
Cash Return on Capital30
Return on Equity26
EBIT Margin11
Gross Profitability34
Accruals85
Owner Earnings Margin20
Sales growth42
Profit Growth4
Long-Term EPS Growth19
Reinvestment61
Price momentum96
Debt load22
Refinancing68
Debt Payback3
Liquidity54
Analyst ratings78
Opinion Changes50
Price Target Upside26
Market mood29
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Curaleaf Holdings clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeTSX
Employees1,786
Websiteir.curaleaf.com
ISINCA23126M1023
Last UpdateApr 2, 2026
Indices
TSX Composite (Canada)
Themes
CannabisAlternative MedicineBiotechnologyCommunity and LifestyleFood and BeverageHealth CareScience and Engineering

Description

Curaleaf Holdings, Inc. is a vertically integrated multi-State cannabis operator in the U.S. The company is a leading global cannabis company, delivering a vertically integrated platform with a broad omnichannel distribution footprint and a diversif…

Analysis

Middle-of-the-road

Curaleaf Holdings, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 88.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
24
2023202420252026

All-time high

49

Jan 2023

All-time low

12

Jan 2024

Average rank

30

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
67
81
56
98
Price/Earnings
80
21
21
1
Price/Book
27
68
16
35
Dividend Yield
1
1
1
1
Value (overall)
55
72
26
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Curaleaf Holdings with its peers
Cronos Group
TOR:CRON
45
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Trulieve Cannabis
CNX:TRUL
39
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Cresco Labs
CNX:CL
43
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
OrganiGram Holdings
TOR:OGI
39
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Scilex
NAQ:SCLX
6
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Grace Therapeutics
NAQ:GRCE
52
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →